Radiofrequency ablation of unresectable liver metastases

Journal of the American College of Surgeons

Volumn 195, Issue 3, 2002, Pages 378-386

  Seidenfeld, Jerome ^a,b   Korn, Allen ^b   Aronson, Naomi ^a  

^a Aronson)   (United States)

^b Blue Cross and Blue Shield Association   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CISPLATIN; DOXORUBICIN; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN; OXALIPLATIN;

ARTIFICIAL EMBOLISM; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CATHETER ABLATION; CLINICAL FEATURE; CLINICAL TRIAL; HUMAN; KIDNEY FAILURE; LIVER METASTASIS; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RADIOFREQUENCY RADIATION; REVIEW; SEPTICEMIA; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR LOCALIZATION; TUMOR VOLUME;

EID: 0036711613     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1072-7515(02)01247-4     Document Type: Article

References (50)

1. Cancer statistics, 2000
2. Surgical ablative therapy of liver tumors
3. Cryotherapy for liver tumors
4. Local-regional therapy for metastatic liver tumors
5. Management of hepatic metastases
6. Therapeutic alternatives in metastatic neuroendocrine tumors
7. Natural history of patients with untreated liver metastases from colorectal cancer
8. Factors influencing survival in patients with untreated hepatic metastases
9. Resection of hepatic metastases from colorectal cancer
10. The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment
11. A retrospective study of the natural history of patients with liver metastases from colorectal cancer
12. Regional therapy for colon and rectal carcinoma liver metastases
13. Surgical therapy of hepatic colorectal metastasis
14. Surgical treatment and other regional treatments for colorectal cancer liver metastases
15. Current treatment for colorectal cancer metastatic to the liver
16. Locoregional treatments for hepatocellular carcinoma
17. Surgical treatment of malignant liver tumours
18. Management strategies for colorectal liver metastases. Part II
19. Local ablation therapy for hepatocellular carcinoma
20. Minimally invasive treatment of malignant hepatic tumors at the threshold of a major breakthrough
21. An appraisal of percutaneous treatment of liver metastases
22. Percutaneous ethanol injection and radio-frequency ablation for the treatment of nonresectable colorectal liver metastases. Techniques and results
23. Percutaneous ultrasound-guided radiofrequency ablation of liver tumors
24. Non-surgical treatment for liver metastases
25. Radiofrequency thermal ablation of liver tumors
26. New trends in the surgical treatment of colorectal cancer liver metastases
27. Technology for radiofrequency thermal ablation of liver tumors
28. Radiofrequency ablation of unresectable primary liver cancer
29. Cryosurgical ablation and radiofrequency ablation for unresectable hepatic malignant neoplasms: A proposed algorithm
30. Percutaneous treatment of small hepatic tumors by an expandable RF needle electrode
31. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer
32. Radio-frequency thermal ablation of liver metastases with a cooled-tip electrode needle. Results of a pilot clinical trial
33. Hepatic metastases. Percutaneous radio-frequency ablation with cooled-tip electrodes
34. Percutaneous US-guided radio-frequency tissue ablation of liver metastases: Treatment and follow-up in 16 patients
35. Long-term follow-up of liver metastases treated with percutaneous US-guided radiofrequency (RF) ablation using internally-cooled electrodes
36. Saline-enhanced radio- frequency tissue ablation in the treatment of liver metastases
37. Percutaneous radiofrequency thermal ablation for liver tumours
38. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma. Long-term results of a prospective randomized trial
39. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver. The Northern California Oncology Group trial
40. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer: A randomized trial
41. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases
42. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial
43. A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver
44. Results of a prospective randomized trial of continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal primaries
45. Results of the hepatic resection of liver metastases from colorectal carcinoma after continuous hepatic arterial infusion of chemotherapy. New strategy for unresectable colorectal liver metastases
46. Adjuvant hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases
47. Results of the Intergroup (Eastern Cooperative Oncology Group [ECOG] and Southwest Oncology Group [SWOG]) prospective randomized study of surgery alone versus continuous hepatic artery infusion of FUDR and continuous systemic infusion of 5FU after hepatic resection for colorectal liver metastases
48. Randomized study of hepatic arterial infusion (HAI) and systemic chemotherapy (SYS) versus SYS alone as adjuvant therapy after resection of hepatic metastases from colorectal cancer
49. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy